IPO
Company Snapshot
Shionogi is a Biotech company, based in Osaka, Japan, founded 1878.
Latest Pulse
- Jul 27, 2026Apnimed Launches $150M IPO For First Sleep Apnea PillShionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.→
- Jul 10, 2026Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea PillApnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.→
Coverage Timeline
newest firstAll Coverage
IPOup to $150M IPO
Apnimed Launches $150M IPO For First Sleep Apnea Pill
Shionogi-backed Apnimed launched a $150 million IPO for its once-daily obstructive sleep apnea pill AD109, targeting a Thursday pricing ahead of a Friday NASDAQ debut.
IPO
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
IPO
Apnimed Files for Nasdaq IPO on First Oral Sleep Apnea Pill
Apnimed, a Shionogi-backed clinical-stage biotech, filed for a Nasdaq IPO under ticker APMD as its lead drug candidate Oxnimbi -- the first investigational oral pill for obstructive sleep apnea -- awaits an FDA decision expected in Q1 2027.